Inhibition of tumor metastasis by targeted daunorubicin and dioscin codelivery liposomes modified with PFV for the treatment of non-small-cell lung cancer

Yuanyuan Wang,1 Min Fu,2 Jingjing Liu,2 Yining Yang,1 Yibin Yu,1 Jinyu Li,1 Weisan Pan,1 Lei Fan,3 Guiru Li,4 Xuetao Li,2 Xiaobo Wang1,31Department of Pharmaceutics, Shenyang Pharmaceutical University, Shenyang, Liaoning, People’s Republic of China; 2School of Pharmacy, Liaoning University...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Wang Y, Fu M, Liu J, Yang Y, Yu Y, Li J, Pan W, Fan L, Li G, Li X, Wang X
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	daunorubicin dioscin liposomes cell penetrating peptides tumor metastasis non-small-cell lung cancer Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/917fca8e753d4332990e6e9321d13398
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:917fca8e753d4332990e6e9321d13398
record_format	dspace
spelling	oai:doaj.org-article:917fca8e753d4332990e6e9321d133982021-12-02T06:26:28ZInhibition of tumor metastasis by targeted daunorubicin and dioscin codelivery liposomes modified with PFV for the treatment of non-small-cell lung cancer1178-2013https://doaj.org/article/917fca8e753d4332990e6e9321d133982019-05-01T00:00:00Zhttps://www.dovepress.com/inhibition-of-tumor-metastasis-by-targeted-daunorubicin-and-dioscin-co-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Yuanyuan Wang,1 Min Fu,2 Jingjing Liu,2 Yining Yang,1 Yibin Yu,1 Jinyu Li,1 Weisan Pan,1 Lei Fan,3 Guiru Li,4 Xuetao Li,2 Xiaobo Wang1,31Department of Pharmaceutics, Shenyang Pharmaceutical University, Shenyang, Liaoning, People’s Republic of China; 2School of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian, Liaoning, People’s Republic of China; 3Department of Pharmacy, 210th Hospital of People’s Liberation Army, Dalian, Liaoning, People’s Republic of China; 4Department of Pharmacy, The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, People’s Republic of ChinaBackground: Chemotherapy for non-small-cell lung cancer (NSCLC) still leads to unsatisfactory clinical prognosis because of poor active targeting and tumor metastasis.Purpose: The objective of this study was to construct a kind of PFV peptide modified targeted daunorubicin and dioscin codelivery liposomes, which could enhance tumor targeting and inhibit tumor cell metastasis.Methods and results: Targeted daunorubicin and dioscin codelivery liposomes were prepared by film dispersion and the ammonium sulfate gradient method. With the ideal physicochemical properties, targeted daunorubicin and dioscin codelivery liposomes exhibited enhanced cellular uptake and showed strong cytotoxicity to tumor cells. The encapsulation of dioscin increased the inhibitory effects of daunorubicin on A549 cells, vasculogenic mimicry (VM) channels and tumor metastasis. The enhanced antimetastatic mechanism of the targeted liposomes was attributed to the downregulation of matrix metalloproteinase-2 (MMP-2), vascular endothelial cadherin (VE-Cad), transforming growth factor-β1 (TGF-β1) and hypoxia inducible factor-1α (HIF-1α). Meanwhile, the targeted daunorubicin and dioscin codelivery liposomes exhibited significant antitumor effects in tumor-bearing mice. H&E staining, immunohistochemistry with Ki-67 and TUNEL assay also showed the promoted antitumor activity of the targeted liposomes.Conclusion: Targeted daunorubicin and dioscin codelivery liposomes may provide an effective strategy for the treatment of NSCLC.Keywords: daunorubicin, dioscin, liposomes, cell penetrating peptides, tumor metastasis, non-small-cell lung cancerWang YFu MLiu JYang YYu YLi JPan WFan LLi GLi XWang XDove Medical Pressarticledaunorubicindioscinliposomescell penetrating peptidestumor metastasisnon-small-cell lung cancerMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 14, Pp 4071-4090 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	daunorubicin dioscin liposomes cell penetrating peptides tumor metastasis non-small-cell lung cancer Medicine (General) R5-920
spellingShingle	daunorubicin dioscin liposomes cell penetrating peptides tumor metastasis non-small-cell lung cancer Medicine (General) R5-920 Wang Y Fu M Liu J Yang Y Yu Y Li J Pan W Fan L Li G Li X Wang X Inhibition of tumor metastasis by targeted daunorubicin and dioscin codelivery liposomes modified with PFV for the treatment of non-small-cell lung cancer
description	Yuanyuan Wang,1 Min Fu,2 Jingjing Liu,2 Yining Yang,1 Yibin Yu,1 Jinyu Li,1 Weisan Pan,1 Lei Fan,3 Guiru Li,4 Xuetao Li,2 Xiaobo Wang1,31Department of Pharmaceutics, Shenyang Pharmaceutical University, Shenyang, Liaoning, People’s Republic of China; 2School of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian, Liaoning, People’s Republic of China; 3Department of Pharmacy, 210th Hospital of People’s Liberation Army, Dalian, Liaoning, People’s Republic of China; 4Department of Pharmacy, The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, People’s Republic of ChinaBackground: Chemotherapy for non-small-cell lung cancer (NSCLC) still leads to unsatisfactory clinical prognosis because of poor active targeting and tumor metastasis.Purpose: The objective of this study was to construct a kind of PFV peptide modified targeted daunorubicin and dioscin codelivery liposomes, which could enhance tumor targeting and inhibit tumor cell metastasis.Methods and results: Targeted daunorubicin and dioscin codelivery liposomes were prepared by film dispersion and the ammonium sulfate gradient method. With the ideal physicochemical properties, targeted daunorubicin and dioscin codelivery liposomes exhibited enhanced cellular uptake and showed strong cytotoxicity to tumor cells. The encapsulation of dioscin increased the inhibitory effects of daunorubicin on A549 cells, vasculogenic mimicry (VM) channels and tumor metastasis. The enhanced antimetastatic mechanism of the targeted liposomes was attributed to the downregulation of matrix metalloproteinase-2 (MMP-2), vascular endothelial cadherin (VE-Cad), transforming growth factor-β1 (TGF-β1) and hypoxia inducible factor-1α (HIF-1α). Meanwhile, the targeted daunorubicin and dioscin codelivery liposomes exhibited significant antitumor effects in tumor-bearing mice. H&E staining, immunohistochemistry with Ki-67 and TUNEL assay also showed the promoted antitumor activity of the targeted liposomes.Conclusion: Targeted daunorubicin and dioscin codelivery liposomes may provide an effective strategy for the treatment of NSCLC.Keywords: daunorubicin, dioscin, liposomes, cell penetrating peptides, tumor metastasis, non-small-cell lung cancer
format	article
author	Wang Y Fu M Liu J Yang Y Yu Y Li J Pan W Fan L Li G Li X Wang X
author_facet	Wang Y Fu M Liu J Yang Y Yu Y Li J Pan W Fan L Li G Li X Wang X
author_sort	Wang Y
title	Inhibition of tumor metastasis by targeted daunorubicin and dioscin codelivery liposomes modified with PFV for the treatment of non-small-cell lung cancer
title_short	Inhibition of tumor metastasis by targeted daunorubicin and dioscin codelivery liposomes modified with PFV for the treatment of non-small-cell lung cancer
title_full	Inhibition of tumor metastasis by targeted daunorubicin and dioscin codelivery liposomes modified with PFV for the treatment of non-small-cell lung cancer
title_fullStr	Inhibition of tumor metastasis by targeted daunorubicin and dioscin codelivery liposomes modified with PFV for the treatment of non-small-cell lung cancer
title_full_unstemmed	Inhibition of tumor metastasis by targeted daunorubicin and dioscin codelivery liposomes modified with PFV for the treatment of non-small-cell lung cancer
title_sort	inhibition of tumor metastasis by targeted daunorubicin and dioscin codelivery liposomes modified with pfv for the treatment of non-small-cell lung cancer
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/917fca8e753d4332990e6e9321d13398
work_keys_str_mv	AT wangy inhibitionoftumormetastasisbytargeteddaunorubicinanddioscincodeliveryliposomesmodifiedwithpfvforthetreatmentofnonsmallcelllungcancer AT fum inhibitionoftumormetastasisbytargeteddaunorubicinanddioscincodeliveryliposomesmodifiedwithpfvforthetreatmentofnonsmallcelllungcancer AT liuj inhibitionoftumormetastasisbytargeteddaunorubicinanddioscincodeliveryliposomesmodifiedwithpfvforthetreatmentofnonsmallcelllungcancer AT yangy inhibitionoftumormetastasisbytargeteddaunorubicinanddioscincodeliveryliposomesmodifiedwithpfvforthetreatmentofnonsmallcelllungcancer AT yuy inhibitionoftumormetastasisbytargeteddaunorubicinanddioscincodeliveryliposomesmodifiedwithpfvforthetreatmentofnonsmallcelllungcancer AT lij inhibitionoftumormetastasisbytargeteddaunorubicinanddioscincodeliveryliposomesmodifiedwithpfvforthetreatmentofnonsmallcelllungcancer AT panw inhibitionoftumormetastasisbytargeteddaunorubicinanddioscincodeliveryliposomesmodifiedwithpfvforthetreatmentofnonsmallcelllungcancer AT fanl inhibitionoftumormetastasisbytargeteddaunorubicinanddioscincodeliveryliposomesmodifiedwithpfvforthetreatmentofnonsmallcelllungcancer AT lig inhibitionoftumormetastasisbytargeteddaunorubicinanddioscincodeliveryliposomesmodifiedwithpfvforthetreatmentofnonsmallcelllungcancer AT lix inhibitionoftumormetastasisbytargeteddaunorubicinanddioscincodeliveryliposomesmodifiedwithpfvforthetreatmentofnonsmallcelllungcancer AT wangx inhibitionoftumormetastasisbytargeteddaunorubicinanddioscincodeliveryliposomesmodifiedwithpfvforthetreatmentofnonsmallcelllungcancer
_version_	1718399949662584832

Inhibition of tumor metastasis by targeted daunorubicin and dioscin codelivery liposomes modified with PFV for the treatment of non-small-cell lung cancer

Ejemplares similares